Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. MittendorfDana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Electronic address: [email protected]Hong ZhangMemorial Sloan Kettering Cancer Center, New York, NY, USACarlos H. BarriosCentro de Pesquisa em Oncologia, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BrazilShigehira SajiFukushima Medical University, Fukushima, JapanKyung Hae JungAsan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaRoberto HeggUniversity of São Paulo, São Paulo, BrazilAndreas KoehlerGemeinschaftspraxis für Haematologie und Onkologie Langen, Langen, GermanyJoohyuk SohnYonsei Cancer Center, Yonsei University Health System, Seoul, South KoreaHiroji IwataAichi Cancer Center Hospital, Nagoya, JapanMelinda L. TelliSchool of Medicine, Stanford University, Stanford, CA, USACristiano FerrarioJewish General Hospital-McGill University, Montréal, QC, CanadaKevin PunieDepartment of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumFrédérique Penault-LlorcaDepartment of Biopathology, Centre Jean Perrin and University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, FranceShilpen PatelAnh Nguyen DucF Hoffmann-La Roche, Basel, SwitzerlandMario Liste-HermosoF Hoffmann-La Roche, Basel, SwitzerlandVidya MaiyaLuciana MolineroJane Yuet Ching HuiNadia HarbeckBreast Center, Department of Gynecology and Obstetrics and Comprehensive Cancer Center of the Ludwig-Maximilians-University, Munich, Germany
2020en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0